Corneal epithelium defects. Disorder of cornea, unspecified
Conditions
Interventions
Intervention group : Description: Patients will receive exosomes derived from Wharton jelly mesenchymal stem cells (WJ-MSCs) with regenerative and anti-inflammatory potential. Exosomes are prepared in
Sponsors
Vice Chancellor for Research, Shiraz University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: Participants aged 18-65 years. Individuals diagnosed with corneal epithelial defects, confirmed by clinical examination and imaging techniques. Patients with moderate to severe corneal epithelial defects that have not responded to conventional treatments. Participants should be generally healthy, without systemic diseases that could affect the study outcomes. Written informed consent obtained from all participants. Patients who have not received any other experimental treatments for corneal epithelial defects in the past 6 months. No active ocular infections or other significant ocular diseases (e.g., glaucoma, uveitis) that could interfere with the study. Willingness and ability to comply with study procedures and follow-up visits.
Exclusion criteria
Exclusion criteria: Patients with uncontrolled systemic diseases such as diabetes, autoimmune disorders, or severe cardiovascular conditions. Presence of other significant ocular diseases (e.g., glaucoma, uveitis) or active ocular infections that could interfere with the study outcomes. Patients who have received other experimental treatments for corneal epithelial defects within the past 6 months. Known allergies to any components of the exosome preparation or related substances. Pregnant or breastfeeding women. Patients currently undergoing immunosuppressive therapy or with a history of organ transplantation. Inability or unwillingness to comply with study procedures and follow-up visits. Any other medical condition that, in the opinion of the investigator, could compromise the safety of the patient or the integrity of the study data.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Improvement of epithelial defects. Timepoint: It is measured in weeks 1, 2 and 4. Method of measurement: Clinical examinations. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMahmoud Nejabat
Shiraz University of Medical Sciences
Outcome results
None listed